Seven Hound Ventures

We look for founders taking on the world's largest problems, and we back them early.

Say Hello → View Portfolio
Track Record
45+
Investments since 2016
4
Public listings
7
Acquisitions
AtaiBeckley
ATAI + Beckley Psytech, both backed early. Acquired by Eli Lilly for about $2.8B (2026).
Acquired · 2026
SpaceX
Nasdaq IPO, 2026 (SPCX).
IPO · 2026
Transcend
Acquired by Otsuka for up to $1.225B (2026).
Acquired · 2026
Beckley Psytech
Acquired by ATAI (2025), forming AtaiBeckley.
Acquired · 2025
Orbillion
Acquired by Fork & Good (2025).
Acquired · 2025
Gilgamesh
AbbVie acquired its lead program, bretisilocin, for up to $1.2B (2025).
Acquired · 2025
Spiritual Gangster
Majority stake acquired by Unified Commerce Group (2023).
Acquired · 2023
The Block
Majority stake acquired by Foresight Ventures at a $70M valuation (2023).
Acquired · 2023
ATAI Life Sciences
Nasdaq IPO, 2021 (ATAI). Later acquired by Eli Lilly as AtaiBeckley.
IPO · 2021
MindMed (now Definium)
Public listing, 2020 (MMED); Nasdaq, 2021 (MNMD).
Listed · 2020
Tilray
Nasdaq IPO, 2018 (TLRY).
IPO · 2018
Our Approach

Early conviction in hard problems.

We are an early, long-term partner to the founders we back.

Portfolio

45+ investments since 2016, across AI, longevity, biotech, fintech, and frontier technology.

In the Press

Selected coverage of the portfolio.

Sean Trigony
About

Founded by Sean Trigony

Seven Hound Ventures is a Los Angeles venture firm founded by Sean Trigony in 2016. Since then we have made 45+ investments across AI, longevity, biotech, fintech, aerospace, and neuroscience.

Los Angeles, California
Contact

Say hello.

We're always open to meeting interesting people doing interesting things.

sean@7hventures.co